Retham Technologies launches functional cryopreserved platelets for research and Prolytix named distributor
Cryopreserved human platelets to improve consistency in platelet-based research
13 Jul 2026Product news
Retham Technologies, Inc. has launched its next-generation functional Retham Cryoplatelets™, a novel solution designed to overcome longstanding challenges in platelet-based research. The company also named Prolytix to be the distributor of the Cryoplatelets.
Reliable access to functional human platelets has long been a major barrier for academic laboratories, pharmaceutical companies, and contract research organizations (CROs). Dependence on freshly drawn donor platelets introduces logistical complexity, high costs, and significant donor variability—limiting reproducibility and scalability.
Retham Cryoplatelets address these challenges by providing a consistent, stable, readily available source of functional human platelets that can be used on demand.
Curtis Jones, VP of Research & Innovation said, “Retham Cryoplatelets were developed to directly address a key challenge we were hearing from potential customers: the limitations of fresh donor platelets for laboratory use.”
Dr. Steven Visuri, CEO of Retham Technologies, added, “We set out to deliver a solution that combines reliable functional performance with operational flexibility. Prolytix is an ideal partner given their scientific expertise and strong presence in the hemostasis and research communities.”
“We are excited to partner with Retham to bring Retham Cryoplatelets to the research market,” said Ryan Dorfman, COO of Prolytix. “This product represents a meaningful advancement for laboratories seeking greater reproducibility and efficiency in platelet-based assays. It aligns closely with our commitment to supporting innovative solutions that meet critical industry needs.”
Retham Cryoplatelets are available for Research Use Only (RUO) and support a broad range of applications, including platelet function assays, drug screening (particularly antibody-based therapeutics), thrombin generation testing, and assay development.
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Frequently asked questions
What are Retham Cryoplatelets and how do they improve platelet-based research?
Retham Cryoplatelets™ are next-generation functional human platelets developed by Retham Technologies, Inc. They provide a consistent, stable, and readily available source of functional platelets for research use. By eliminating dependence on freshly drawn donor platelets, they reduce logistical complexity, costs, and donor variability, improving reproducibility and scalability in platelet-based assays and related laboratory applications.
Who is distributing Retham Cryoplatelets and why is Prolytix an ideal partner?
Prolytix, a leader in coagulation and hematology services and products, is the distributor of Retham Cryoplatelets. According to Retham’s CEO Dr. Steven Visuri, Prolytix is an ideal partner due to its scientific expertise and strong presence in the hemostasis and research communities, supporting broader access to this platelet research innovation.
What research applications are supported by Retham Cryoplatelets for laboratories and CROs?
Retham Cryoplatelets, available for Research Use Only (RUO), support platelet function assays, drug screening — particularly antibody-based therapeutics — thrombin generation testing, and assay development. They maintain responsiveness across multiple assay platforms, offering academic laboratories, pharmaceutical companies, and contract research organizations a reliable tool for reproducible and efficient platelet-based research.